The news came as the regulator was set to convene an independent panel Friday that will likely vote to authorize the vaccine, making it the third available in the country hit hardest by the coronavirus pandemic.

In large clinical trials, the J&J vaccine’s efficacy against severe disease was 85.9 percent in the United States, 81.7 percent in South Africa, and 87.6 percent in Brazil.

Overall, among 39,321 participants across all regions, the efficacy against severe Covid-19 was 85.4 percent, but it fell to 66.1 percent when including moderate forms of the disease.

Crucially, analyses of different demographic groups revealed no marked differences across age, race, or people with underlying conditions.

The vaccine was generally well-tolerated, with no reports of severe allergic reactions (anaphylaxis), which have been seen in rare cases for the Pfizer and Moderna shots.

Mild to moderate reactions, like injection-site pain, headache, fatigue and muscle pains were more likely to occur in younger participants than older.

There were no reported deaths in the vaccine group, but five in the placebo group.

“The analysis supported a favorable safety profile with no specific safety concerns identified that would preclude issuance of an EUA (emergency use authorization),” the FDA wrote.

White House Coronavirus Response Coordinator Jeff Zients told reporters that if authorized, the federal government would seek to distribute three to four million doses next week.

“Johnson and Johnson has announced it aims to deliver a total of 20 million doses by the end of March,” he continued, adding the government was trying to speed up the delivery of the contracted 100 million doses, which the company has promised by the end of June.

A third vaccine is seen as a vital means to ramp up the immunization rate in the United States, where more than 500,000 people have lost their lives to the coronavirus.

Some 65 million people in America have so far received at least one shot of either the Pfizer or Moderna vaccines — but unlike those, the J&J vaccine requires just one dose, and is stored at fridge temperatures.

The trade-off is slightly less protection against mild or moderate forms of Covid-19.

“The vaccine was effective in preventing COVID-19 using a less restrictive definition of the disease and for more severe disease, including COVID-19 requiring medical intervention, considering all cases starting 14 days after vaccination,” the FDA wrote in its briefing document.

“Although a lower efficacy overall was observed in South Africa, where there was a predominance of B.1.3.5 lineage during the time period of this study, vaccine efficacy against severe/critical COVID-19 was similarly high across the United States, South Africa, and Brazil,” it added.

There was a hint, based on preliminary data, that the vaccine might be effective against asymptomatic infection.

But “this finding needs to be further investigated with additional data,” wrote the company in a separate document made available by the FDA.

The J&J vaccine uses a common-cold causing adenovirus, which has been modified so that it can’t replicate, to carry the DNA for a key protein of the coronavirus into human cells.

This makes those cells produce that protein, which in turn trains the human immune system should it encounter the real virus.

Other adenovirus vector vaccines against Covid-19 include those made by AstraZeneca-Oxford and Russia’s Sputnik V.

AFP